Cargando…

Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19

Advanced age or preexisting comorbidities have been characterized as risk factors for severe coronavirus disease 2019 (COVID-19) cases requiring hospitalization and intensive care. In recent years, clonal hematopoiesis (CH) of indeterminate potential (CHIP) has emerged as a risk factor for chronic i...

Descripción completa

Detalles Bibliográficos
Autores principales: Duployez, Nicolas, Demonchy, Jordane, Berthon, Céline, Goutay, Julien, Caplan, Morgan, Moreau, Anne-Sophie, Bignon, Anne, Marceau-Renaut, Alice, Garrigue, Delphine, Raczkiewicz, Imelda, Geffroy, Sandrine, Bucci, Maxime, Alidjinou, Kazali, Demaret, Julie, Labalette, Myriam, Brousseau, Thierry, Dupont, Annabelle, Rauch, Antoine, Poissy, Julien, Susen, Sophie, Preudhomme, Claude, Quesnel, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409316/
https://www.ncbi.nlm.nih.gov/pubmed/32708264
http://dx.doi.org/10.3390/cancers12071992
_version_ 1783568038286589952
author Duployez, Nicolas
Demonchy, Jordane
Berthon, Céline
Goutay, Julien
Caplan, Morgan
Moreau, Anne-Sophie
Bignon, Anne
Marceau-Renaut, Alice
Garrigue, Delphine
Raczkiewicz, Imelda
Geffroy, Sandrine
Bucci, Maxime
Alidjinou, Kazali
Demaret, Julie
Labalette, Myriam
Brousseau, Thierry
Dupont, Annabelle
Rauch, Antoine
Poissy, Julien
Susen, Sophie
Preudhomme, Claude
Quesnel, Bruno
author_facet Duployez, Nicolas
Demonchy, Jordane
Berthon, Céline
Goutay, Julien
Caplan, Morgan
Moreau, Anne-Sophie
Bignon, Anne
Marceau-Renaut, Alice
Garrigue, Delphine
Raczkiewicz, Imelda
Geffroy, Sandrine
Bucci, Maxime
Alidjinou, Kazali
Demaret, Julie
Labalette, Myriam
Brousseau, Thierry
Dupont, Annabelle
Rauch, Antoine
Poissy, Julien
Susen, Sophie
Preudhomme, Claude
Quesnel, Bruno
author_sort Duployez, Nicolas
collection PubMed
description Advanced age or preexisting comorbidities have been characterized as risk factors for severe coronavirus disease 2019 (COVID-19) cases requiring hospitalization and intensive care. In recent years, clonal hematopoiesis (CH) of indeterminate potential (CHIP) has emerged as a risk factor for chronic inflammatory background and subsequent aging-associated diseases. The purpose of this study was to identify biological factors (particularly leukocyte subtypes and inflammatory markers) associated with a risk of clinical deterioration (i.e., orotracheal intubation (OTI)) and to determine whether CH was likely to influence clinical and biological behavior in patients with severe COVID-19 requiring hospitalization. Here, we describe clinical and biological features, including the screening of CHIP mutants in a well-annotated cohort of 122 hospitalized patients with a laboratory-confirmed diagnosis of COVID-19 (55% requiring OTI). We showed that elevated white blood cell counts, especially neutrophils and high C-reactive protein (CRP) levels at admission, were associated with an increased requirement of OTI. We noticed a high prevalence of CH (25%, 38%, 56%, and 82% of patients aged <60 years, 60–70 years, 70–80 years, and >80 years) compared to a retrospective cohort of patients free of hematological malignancy explored with the same pipelines (10%, 21%, 37%, and 44%). However, the existence of CH did not significantly impact clinical outcome, including OTI or death, and did not correlate with other laboratory findings.
format Online
Article
Text
id pubmed-7409316
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74093162020-08-25 Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19 Duployez, Nicolas Demonchy, Jordane Berthon, Céline Goutay, Julien Caplan, Morgan Moreau, Anne-Sophie Bignon, Anne Marceau-Renaut, Alice Garrigue, Delphine Raczkiewicz, Imelda Geffroy, Sandrine Bucci, Maxime Alidjinou, Kazali Demaret, Julie Labalette, Myriam Brousseau, Thierry Dupont, Annabelle Rauch, Antoine Poissy, Julien Susen, Sophie Preudhomme, Claude Quesnel, Bruno Cancers (Basel) Article Advanced age or preexisting comorbidities have been characterized as risk factors for severe coronavirus disease 2019 (COVID-19) cases requiring hospitalization and intensive care. In recent years, clonal hematopoiesis (CH) of indeterminate potential (CHIP) has emerged as a risk factor for chronic inflammatory background and subsequent aging-associated diseases. The purpose of this study was to identify biological factors (particularly leukocyte subtypes and inflammatory markers) associated with a risk of clinical deterioration (i.e., orotracheal intubation (OTI)) and to determine whether CH was likely to influence clinical and biological behavior in patients with severe COVID-19 requiring hospitalization. Here, we describe clinical and biological features, including the screening of CHIP mutants in a well-annotated cohort of 122 hospitalized patients with a laboratory-confirmed diagnosis of COVID-19 (55% requiring OTI). We showed that elevated white blood cell counts, especially neutrophils and high C-reactive protein (CRP) levels at admission, were associated with an increased requirement of OTI. We noticed a high prevalence of CH (25%, 38%, 56%, and 82% of patients aged <60 years, 60–70 years, 70–80 years, and >80 years) compared to a retrospective cohort of patients free of hematological malignancy explored with the same pipelines (10%, 21%, 37%, and 44%). However, the existence of CH did not significantly impact clinical outcome, including OTI or death, and did not correlate with other laboratory findings. MDPI 2020-07-21 /pmc/articles/PMC7409316/ /pubmed/32708264 http://dx.doi.org/10.3390/cancers12071992 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Duployez, Nicolas
Demonchy, Jordane
Berthon, Céline
Goutay, Julien
Caplan, Morgan
Moreau, Anne-Sophie
Bignon, Anne
Marceau-Renaut, Alice
Garrigue, Delphine
Raczkiewicz, Imelda
Geffroy, Sandrine
Bucci, Maxime
Alidjinou, Kazali
Demaret, Julie
Labalette, Myriam
Brousseau, Thierry
Dupont, Annabelle
Rauch, Antoine
Poissy, Julien
Susen, Sophie
Preudhomme, Claude
Quesnel, Bruno
Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19
title Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19
title_full Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19
title_fullStr Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19
title_full_unstemmed Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19
title_short Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19
title_sort clinico-biological features and clonal hematopoiesis in patients with severe covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409316/
https://www.ncbi.nlm.nih.gov/pubmed/32708264
http://dx.doi.org/10.3390/cancers12071992
work_keys_str_mv AT duployeznicolas clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT demonchyjordane clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT berthonceline clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT goutayjulien clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT caplanmorgan clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT moreauannesophie clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT bignonanne clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT marceaurenautalice clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT garriguedelphine clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT raczkiewiczimelda clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT geffroysandrine clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT buccimaxime clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT alidjinoukazali clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT demaretjulie clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT labalettemyriam clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT brousseauthierry clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT dupontannabelle clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT rauchantoine clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT poissyjulien clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT susensophie clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT preudhommeclaude clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT quesnelbruno clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19
AT clinicobiologicalfeaturesandclonalhematopoiesisinpatientswithseverecovid19